Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Show more
Location: 100 King Street West, Toronto, ON, M5X 1C9, Canada | Website: https://www.cybin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
175.2M
52 Wk Range
$4.81 - $13.88
Previous Close
$7.38
Open
$7.95
Volume
442,098
Day Range
$7.55 - $7.97
Enterprise Value
40.2M
Cash
136.3M
Avg Qtr Burn
-25.22M
Insider Ownership
238.24%
Institutional Own.
48.73%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CYB003 (Deuterated Psilocin Oral) Details Major Depressive Disorder (MDD) adjunct | Phase 3 Data readout | |
CYB004 (Deuterated Dimethyltryptamine Intramuscular) Details Generalized Anxiety Disorder (GAD) | Phase 2 Data readout |